Chemoprevention of Bladder CA by soybean bioactive comp.
Chemoprevention of Bladder CA by soybean bioactive comp.
批准号:
6897037
负责人:
JIN-RONG ZHOU
金额:
$30.26万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-06-01 至 2007-05-31
关键词:
SCID mouseangiogenesisangiopoietinsapoptosisbiomarkerbladder neoplasmcell proliferationchemopreventioncyclin dependent kinasediet therapydietary supplementsgene expressiongenisteinimmunocytochemistrymicroarray technologymucosanutrition aspect of cancernutrition related tagphytoestrogenspolymerase chain reactionsoybeans
中文摘要
描述(由申请人提供):该提案的重点是大豆生物活性成分对膀胱癌的化学预防活性。该假设是,增加大豆生物活性成分的饮食消费可以作为一种有效的营养方案,用于通过调节膀胱肿瘤血管生成、凋亡和/或增殖来预防膀胱癌进展和转移。支持这一假设的基本原理是基于以下几点:(1)大豆生物活性成分通过血液循环和直接接触膀胱粘膜发挥其抗膀胱癌的作用,以及(2)我们的动物研究和体内机制研究表明,大豆植物化学物质通过诱导肿瘤细胞凋亡,抑制肿瘤增殖和抑制肿瘤血管生成来抑制膀胱肿瘤的进展。在这个建议中,三个具体的目标将被设计来测试我们的假设,通过使用临床相关的原位膀胱模型。具体目的1是确定大豆组分对高分化、低转移性(RT 4)和低分化、高转移性(253 J B-V)人膀胱肿瘤的原位生长和/或转移的影响。将评价大豆组分(大豆黄酮去除的大豆蛋白、大豆植物化学浓缩物和大豆染料木苷)对体内RT 4和253 J-B-V肿瘤生长和转移的影响。具体目标2是确定大豆组分对与肿瘤细胞凋亡和增殖以及肿瘤血管生成相关的肿瘤生物标志物表达的影响。这些凋亡和增殖生物标志物包括(a)凋亡指数和相关的凋亡诱导物(p53、p21/wafl、bax、TNF-α)和凋亡阻遏物(bcl-2、bcl-xl),(B)增殖指数和细胞周期相关的细胞周期蛋白(A、D、E)和细胞周期蛋白依赖性激酶(cdks 2、4、6)。我们的体外微阵列分析表明,与血管生成网络相关的标记物是受大豆成分显著调节的重要基因之一。这些血管生成生物标志物包括肿瘤血管生成因子(VEGF、bFGF、血管生成素-1)和抗血管生成因子血管生成素-2。采用RT-PCR和免疫组化结合图像分析的方法检测上述分子标志物的表达。具体目标3是通过微阵列cDNA芯片技术,进一步阐明基因和大豆生物活性成分在体外和体内对膀胱癌调控的相互作用机制。通过使用含有与约12,000个全长人cDNA互补的序列的寡核苷酸阵列,将在体外和体内样品中测定剂量依赖性和时间依赖性mRNA表达模式。这些显著不同的基因转录本中的一些将通过RT-PCR证实。通过将营养学、分子生物学和遗传学整合到膀胱癌预防研究中,从拟议的研究中获得的结果有望为利用膳食大豆预防膀胱癌提供重要的见解。
英文摘要
DESCRIPTION (provided by applicant): This proposal is focused on the chemopreventive activity of soybean bioactive components on bladder cancer. The hypothesis is that increased dietary consumption of soybean bioactive components may serve as an effective nutritional regimen for the prevention of bladder cancer progression and metastasis by modulating bladder tumor angiogenesis, apoptosis and/or proliferation. The rationale for supporting this hypothesis is based on the followings: (1) Soy bioactive components exert their effects on anti-bladder cancer via both blood circulation and direct contact with the mucosa of the bladder, and (2) Our animal studies and in vivo mechanistic studies indicated that soy phytochemicals inhibited bladder tumor progression by inducing tumor cell apoptosis, inhibiting tumor proliferation and inhibiting tumor angiogenesis. In this proposal, three specific aims will be designed to test our hypothesis by using a clinically relevant orthotopic bladder model. Specific Aim 1 is to determine the effect of soybean components on orthotopic growth and/or metastasis of both well-differentiated, low metastatic (RT4) and poorly differentiated, highly metastatic (253J B-V) human bladder tumors. Soybean components (soy isoflavone-depleted soy protein, soy phytochemical concentrate, and soy genistin) will be evaluated for their effects on the growth and metastasis of both RT4 and 253J-B-V tumors in vivo. Specific aim 2 is to determine the effect of soybean components on the expression of tumor biomarkers that are related to tumor cell apoptosis and proliferation and tumor angiogenesis. These apoptotic and proliferation biomarkers include (a) apoptotic index and related apoptosis inducers (p53, p21/wafl, bax, TNF-alpha) and apoptosis repressors (bcl-2, bcl-xl), (b) proliferation index and cell cycle related cyclins (A, D, E) and cyclin-dependent kinases (cdks 2, 4, 6). Our in vitro microarray assays have suggested that markers that are related to angiogenesis network are among important genes that are significantly modulated by soy components. These angiogenic biomarkers include tumor angiogenic factors (VEGF, bFGF, angiopoietin-1) and anti-angiogenic factor angiopoietin-2. RT-PCR and immunohistochemistry followed by image analysis will be applied to determine the expression of above molecular markers. Specific aim 3 is to further elucidate mechanisms involved in the interactive affect of genes and soy bioactive components on bladder cancer modulation in vitro and in vivo by employing microarrayed cDNA chip technology. By using an oligonucleotide array containing sequences complementary to about 12,000 full-length human cDNAs, both dose-dependent and time-dependent mRNA expression patterns will be determined in both in vitro and in vivo samples. Some of these significantly different gene transcripts will be confirmed by RT-PCR. Results derived from the proposed studies by integrating nutrition, molecular biology and genetics in bladder cancer prevention research will be expected to provide significant insight into the utilization of dietary soy in the prevention of bladder cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tanshinones for prevention of bladder cancer progression
-
批准号:8296497
-
项目类别:
-
资助金额:$8.7万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Targeting prostate cancer stem cells to delay prostate cancer progression
-
批准号:8190865
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Tanshinones for prevention of bladder cancer progression
-
批准号:8203196
-
项目类别:
-
资助金额:$8.7万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Targeting prostate cancer stem cells to delay prostate cancer progression
-
批准号:8286889
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2011
-
负责人:JIN-RONG ZHOU
-
依托单位:
Metabolic Syndrome as Pancreatic Cancer Etiology
-
批准号:7469288
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2008
-
负责人:JIN-RONG ZHOU
-
依托单位:
Metabolic Syndrome as Pancreatic Cancer Etiology
-
批准号:7609157
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2008
-
负责人:JIN-RONG ZHOU
-
依托单位:
Oldenlandia diffusa for prostate cancer treatment
-
批准号:7314416
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Parental metabolic status and offspring cancer risks
-
批准号:7491579
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Synergy between phytochemicals for prostate cancer prevention
-
批准号:7322669
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Oldenlandia diffusa for prostate cancer treatment
-
批准号:7503961
-
项目类别:
-
资助金额:$20.4万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Parental metabolic status and offspring cancer risks
-
批准号:7322672
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Synergy between phytochemicals for prostate cancer prevention
-
批准号:7491565
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2007
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genistien and prevention of HER2-overexpressing breast *
-
批准号:6878387
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genistien and prevention of HER2-overexpressing breast *
-
批准号:6951520
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Prevention of bladder cancer progression by sulforaphane
-
批准号:6878391
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Prevention of bladder cancer progression by sulforaphane
-
批准号:6951880
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2004
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder Cancer by soybean
-
批准号:6575544
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Genes Modulated by Soy in Prostate Cancer Progression
-
批准号:6618448
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder CA by soybean bioactive comp.
-
批准号:7068530
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
Chemoprevention of Bladder CA by soybean bioactive comp.
-
批准号:6751663
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2003
-
负责人:JIN-RONG ZHOU
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
-
批准号:82372007
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:谢文晖
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
-
批准号:32070790
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:徐小燕
-
依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
-
批准号:81200692
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:陈凌
-
依托单位:
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
-
批准号:81171370
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:朱朝晖
-
依托单位:
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
-
批准号:81172267
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:高文涛
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
-
批准号:81171834
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:鲁峰
-
依托单位:
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
-
批准号:81171369
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2011
-
负责人:李方
-
依托单位:
核素靶向示踪肿瘤新生血管作用位点研究
-
批准号:81071183
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:王荣福
-
依托单位: